Pancreatic Cancer Screening: @danafarber.bsky.social's Dr. Asaf Maoz discusses potential blood-based biomarkers with @ascopost.bsky.social. ➡️bit.ly/4enYymn
ASCO 2026 ssessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals ( Asaf Maoz, MD , of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective a Abstract 10527).
